

Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp

著者	中嶋 一史
著者別表示	Nakashima Kazufumi
journal or publication title	博士論文本文Full
学位授与番号	13301甲第4173号
学位名	博士（医学）
学位授与年月日	2015-03-23
URL	http://hdl.handle.net/2297/43565

doi: <https://doi.org/10.1186/1471-2334-14-43>



RESEARCH ARTICLE

Open Access

Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp

Kazufumi Nakashima¹, Kazuyoshi Shigehara^{1,2*}, Shohei Kawaguchi¹, Akira Wakatsuki³, Yoshitomo Kobori⁴, Kazuyoshi Nakashima⁵, Yasunori Ishii⁶, Masayoshi Shimamura², Toshiyuki Sasagawa⁷, Yasuhide Kitagawa¹, Atsushi Mizokami¹ and Mikio Namiki¹

Abstract

Background: Oropharyngeal squamous cell carcinoma (OSCC) has shown a gradual increase in male predominance due to the increasing incidence of human papillomavirus (HPV)-associated OSCC. However, the mode of HPV transmission to the oral cavity is poorly understood, and little is known about the epidemiology of oral HPV infection in men. The prevalence rates of HPV, *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp. were compared in the oropharynx (oral cavity) and urine of male Japanese patients attending a sexually transmitted disease clinic.

Methods: The study population consisted of 213 men aged 16 – 70 years old (mean: 34.4 years old). Oropharyngeal gargles and urine were collected, and sedimented cells were preserved in liquid-based cytology solution. After DNA extraction, β -globin and infectious organisms were analyzed by a PCR-based method. The HPV genotype was determined by HPV GenoArray test.

(Continued on next page)

* Correspondence: kshigehara0415@yahoo.co.jp

¹Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan

²Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan

Full list of author information is available at the end of the article

(Continued from previous page)

Results: β -Globin was positive in 100% and 97.7% of oral and urine samples, respectively. HPV detection rates were 18.8% and 22.1% in oral and urine samples, respectively, suggesting that the prevalence of HPV infection in the oral cavity was similar to that in the urinary tract. *N. gonorrhoeae* was more prevalent in oral (15.6%) than urine samples (9.1%), whereas *C. trachomatis* was detected more frequently in urine (15.9%) than oral samples (4.2%). The detection rates of *M. genitalium*, *M. hominis*, and *Ureaplasma* spp. were 5.2%, 10.3%, and 16.0% in oral samples, and 7.7%, 6.3%, and 19.2% in urine, respectively. There were no significant differences in the detection rates of *Mycoplasma* spp. and *Ureaplasma* spp. between anatomical locations. The distribution of HPV types were similar in oral and urine samples, and HPV16 was the most common type. The majority of men with HPV infection in both the oral cavity and urine had concordant oral and urinary HPV infection. The presence of urinary HPV infection was an independent risk factor of oral HPV infection, with an odds ratio of 3.39 (95% CI: 1.49 – 7.71), whereas oral gonococcal infection was inversely correlated with oral HPV infection (odds ratio: 0.096; 95% CI: 0.01 – 0.77).

Conclusions: Oral HPV infection commonly occurs in sexually active men, and is significantly correlated with urinary HPV infection.

Keywords: Human papillomavirus, Oral infection, Mycoplasma, Ureaplasma, Liquid-based cytology

Background

Human papillomavirus (HPV) infection is a necessary element for the development of virtually all cases of cervical cancer in women [1], and has also been identified as a risk factor for the development of anal, penile, and oropharyngeal cancers [2-4]. In particular, oropharyngeal squamous cell carcinoma (OSCC) has shown a gradual increase in male predominance since the 1970s, despite reductions in smoking, as a result of the increasing incidence of HPV-associated OSCC. Indeed, a recent study indicated that HPV detection represented about 70% of all OSCCs in the USA in 2007, compared with 10% in the 1980s [5], and another large-scale study indicated that the HPV prevalence of 323 OSCC cases was 63.8% (206 cases) [6]. A Japanese epidemiological report in 2008 by the Ministry of Health, Labour and Welfare found that the incidence of OSCC has also been gradually increasing over the last three decades in Japan, which is likely due to the increase in HPV-positive cases [7]. HPV-associated OSCC is now a well-defined entity with well-known characteristics that include young age, good performance status, male gender, nonsmoking, and high-risk sexual behavior [6,8].

Cervical HPV infection appears to occur frequently within a few years of sexual debut, and its prevalence decreases with increasing age from the peak prevalence in younger women [9]. Sexually transmitted cervical HPV infection, when it persists for 10 – 15 years, presents a risk of developing precancerous lesions of the cervix, which can progress to invasive cervical cancer. On the other hand, HPV-associated OSCC is also thought to be induced by oropharyngeal HPV infection. However, the mode of transmission of HPV to the oral cavity is less well understood, and little is known about the epidemiology of oral pharyngeal HPV infection in men.

In the present study, we investigated the prevalence of HPV infection and HPV types in the oropharynx (oral cavity) and urine of male Japanese patients who attended a sexually transmitted disease (STD) outpatient clinic, and the concordance of infected HPV types between these two infection sites. In addition, the infection statuses of *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp. were also examined in oral and urine samples, and we investigated the possible association of oral HPV infection with these infectious organisms.

Methods

Study subjects

A total of 213 male Japanese patients who attended the STD outpatient clinic of Kanazawa University Hospital (Kanazawa, Japan), Ishikawa Prefectural Central Hospital (Kanazawa, Japan), Dokkyo Medical School, Koshigaya Hospital (Koshigaya, Japan), Wakatsuki Clinic (Osaka, Japan), and Nakashima Clinic (Kanazawa, Japan) were enrolled in this study. All participants were men who had sex with women, and homosexual or bisexual men were excluded from the study. The ethics committee of Kanazawa University Graduate School of Medicine approved this study. Oropharyngeal gargle and urine samples were obtained from each subject after obtaining their written informed consent. A clinical diagnosis of urethritis was defined as ≥ 5 polymorphonuclear leukocytes per high-power field in collected urethral swabs.

To obtain oral specimens, each subject swished 15 mL of normal saline around their oral cavity, gargled with their head tilted back for 10 – 20 s, and then expectorated into a specimen cup. In addition, all urine from one urination for each patient was collected in an individual urine cup, and 15 mL was placed into a separate tube. Each sample (15 mL) was centrifuged at

approximately 1500 × g for 10 min, and the sediment was placed into a separate tube containing 2.5 mL of preservative solution for liquid-based cytology (LiquiPrep; LGM International Inc., Melbourne, FL, USA) and stored at 4°C until use.

HPV-DNA test and genotyping

Aliquots of 800 µL of preservative solution containing cell samples were centrifuged at approximately 1500 × g for 10 min, and the supernatants were discarded. The cell pellets were washed twice with 300 µL of 10 mmol/L Tris-HCl (pH 8.0). DNA was extracted from the cells using a DNA extraction kit (SMI Test; G&G Science Co., Fukushima, Japan) according to the manufacturer's instructions. The β-globin gene was first amplified to confirm the adequacy of the extracted DNA in all samples. In β-globin-positive samples, HPV-DNA was tested by modified GP5+/GP6+ polymerase chain reaction (PCR) as described previously [10].

HPV genotyping was performed using HPV GenoArray Test Kits (HybriBio Limited, Chaozhou, China) according to the manufacturer's protocol. This assay can be used to determine 21 HPV genotypes, consisting of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), 5 low-risk HPV types (6, 11, 42, 43, and 44), and two unknown-risk types (53 and CP8304), by flow-through hybridization using HPV-DNA amplified by PCR [11]. Internal control and HPV genotype were visualized simultaneously as spots at the position of control and each HPV type probe on the same membranes [11]. This is a kit that has recently become commercially available, and has shown good agreement (93.8%) in detection of HPV types with the results of the Amplicor HPV test, as described previously [12].

Detection of *N. gonorrhoeae*, *C. trachomatis*, *M. genitalium*, *M. hominis*, and *Ureaplasma* spp. (biovars 1 and 2)

N. gonorrhoeae was detected in each liquid-based sample by PCR using specific primers targeting the *N. gonorrhoeae orf1* gene [13]. For the 427 urethral swabs, the sensitivity, specificity, positive predictive value, negative predictive value for this PCR method were reported to be 100%, 98%, 99.7%, and 100%, respectively. The primer for *C. trachomatis* amplified a 205-bp fragment of the 16S rRNA gene, as described previously, and had sensitivity and specificity of 97.9% and 98.7%, respectively [14].

Mycoplasma genitalium, *Mycoplasma hominis*, and *Ureaplasma* spp. (biovars 1 and 2) were detected by multiplex PCR assay as described by Stellrecht et al. [15,16]. This Multiplex PCR is a simple and convenient method performed with primers specific for highly conserved regions in the urease gene of *Ureaplasma* spp., the 140-kDa adhesion protein gene of *M. genitalium*, and the 16S rRNA gene of *M. hominis*, yielding bands of

403 – 448 bp, 282 bp, and 334 bp, respectively [16]. The overall sensitivity, specificity, and positive and negative predictive values of multiplex PCR analyses for detection of *Mycoplasma* spp. and *Ureaplasma* spp. were 87%, 96%, 94%, and 93%, respectively, with an analytical lower limit of detection of < 12.5 colony forming units (cfu) for *Ureaplasma* spp., *M. genitalium*, and *M. hominis*, even if these organisms were mixed together.

Statistical analysis

The chi-square test was used to compare HPV-positive rates between the two anatomical sites among all 213 patients. Univariate and multivariate analysis using unconditional direct logistic regression analysis for all variables was performed to determine the risk factors for detection of oral HPV infection, and the odds ratios (OR) and 95% confidence intervals (CI) were calculated. The SPSS statistical software package (version 17.0; SPSS Inc., Chicago, IL) was used for all analyses, and *P* < 0.05 was taken to indicate statistical significance.

Results

Among the 213 participants aged 16 – 70 years (mean ± SD; 34.3 ± 10.2 years), 91 (43%) had urethritis, comprised of 17 gonococcal, 31 chlamydial, 2 gonococcal and chlamydial, and 41 non-gonococcal and non-chlamydial infections (Table 1). The other 122 patients had no evidence of urethritis. Among these 122 patients, two with painful clusters of genital sores consisting of vesicles on the penile surface were diagnosed as having *Herpes genitalis*, and *Trichomonas* was incidentally identified in one patient based on urinary microscopic examination. There were no patients with any pharyngitis-like symptoms.

Positive amplification of the β-globin gene was observed in all 213 (100%) of the oral samples and in 208 (97.7%) of the urine samples (Table 2). Among the β-globin-positive samples, the HPV detection rates were 18.8% in oral samples and 22.1% in urine samples. High-

Table 1 Patient backgrounds (n = 213)

Variables	n
Mean age (range)	34.3 (16 – 70)
Number of patients with urethritis	91 (43%)
Gonococcal	17
Chlamydial	31
Gonococcal and chlamydial	2
Non-gonococcal and non-chlamydial	41
Number of patients non-urethritis	122 (57%)
<i>Herpes genitalis</i>	2
Asymptomatic <i>Trichomonas</i> infection	1
Asymptomatic (for STD check)	119

STD, sexually transmitted disease.

Table 2 Results of PCR analysis of oral samples and urine samples by liquid-based cytology

	Oral cavity (n = 213)	Urine (n = 213)	P-value
Number of adequate samples (%)	213 (100%)	208 (97.7%)	
HPV detection rate (%)	40 (18.8%)	46 (22.1%)	0.331
High-risk HPV detection rate (%)	30 (14.1%)	32 (15.4%)	0.575
Low-risk HPV detection rate (%)	12 (5.6%)	19 (9.1%)	0.276
Frequency of single-type HPV infection (%)	30 (75.0%)	24 (52.2%)	0.029
<i>N. gonorrhoeae</i> (%)	36 (15.6%)	19 (9.1%)	0.018
<i>C. trachomatis</i> (%)	9 (4.2%)	33 (15.9%)	< 0.001
<i>M. genitalium</i> (%)	11 (5.2%)	16 (7.7%)	0.290
<i>M. hominis</i> (%)	22 (10.3%)	13 (6.3%)	0.130
<i>Ureaplasma</i> spp. (%)	34 (16.0%)	40 (19.2%)	0.378

PCR, polymerase chain reaction; HPV, human papillomavirus.

risk HPV was detected in 14.1% of oral samples and in 15.4% of urine samples. There were no significant differences in the prevalence rates of HPV or high-risk HPV between oral and urine samples. *N. gonorrhoeae* was more prevalent in oral samples (15.6%) than in urine samples (9.1%), whereas *C. trachomatis* was detected more frequently in urine samples (15.9%) than in those from the oral cavity (4.2%). On the other hand, the detection rates of *M. genitalium*, *M. hominis*, and *Ureaplasma* spp. were 5.2%, 10.3%, and 16.0% in the oral cavity and 7.7%, 6.3%, and 19.2% in urine, respectively. The differences in detection rates between oral and urine samples were not significant.

The HPV type distributions were similar in oral and urinary samples, and HPV16 was the most common type, followed by types 6, 18, 11, and 33 (Table 3). However, single-type HPV infection was frequently identified in the oral cavity (30/40 cases; 75.0%), whereas multiple-type HPV infection was found more frequently in urine samples than in oral samples (Table 2). Moreover, there were 18 cases with HPV infection at both anatomical sites (Table 4). Among these cases, the detected HPV types in oral and urinary samples were in complete agreement in 8 cases (44.4%), and were consistently similar in 16 cases (88.9%).

In addition, we attempted to identify the risk factors for oral HPV infection. Multivariate analysis indicated that the presence of urinary HPV infection was an independent risk factor for oral HPV infection, with an odds ratio of 3.39 (95% CI: 1.49 – 7.71) (Table 5). Moreover, oral gonococcal infection was inversely correlated with oral HPV infection (odds ratio: 0.096; 95% CI: 0.01 – 0.77). On the other hand, age, presence of urethritis, and coinfection of the urinary tract with *C. trachomatis*, *M. genitalium*, *M. hominis*, *Ureaplasma* spp., and *N. gonorrhoeae* were not correlated with oral HPV infection.

Table 3 Type-specific prevalence rates of HPV in oral and urine samples

HPV type	Oral cavity (n = 40) n (%)	Urine (n = 46) n (%)
High-risk type		
16	17 (42.5)	19 (41.3)
18	7 (17.5)	11 (23.9)
33	5 (12.5)	6 (13.0)
39	-	1 (2.2)
52	1 (2.5)	3 (6.5)
53	-	2 (4.3)
58	1 (2.5)	3 (6.5)
59	1 (2.5)	2 (4.3)
66	-	1 (2.2)
Low-risk type		
6	8 (20.0)	11 (23.9)
11	5 (12.5)	10 (21.7)
Unknown type		
	1 (2.5)	2 (4.3)

HPV, human papillomavirus.

Discussion

There is substantial molecular evidence suggesting a role for HPV infection in the pathogenesis of OSCC, and the incidence of HPV-associated OSCC has been gradually increasing worldwide [5,6]. The development of oral HPV infection is essential in the first phase of the development of HPV-associated OSCC, and oral sexual intercourse is suspected to be a route of oral HPV infection. Indeed, a case-control study of HPV and OSCC demonstrated that oral HPV infection is strongly associated with OSCC, and indicated that a high lifetime number of oral sex partners (more than 6 partners) was an independent risk factor for OSCC, with an odds ratio of 3.4 (95% CI: 1.3 – 8.8) [17]. However, little information is available regarding the epidemiological status of oral HPV infection, especially in men. Thus, the prevalence of HPV infection in the oropharynx (oral cavity) and urine in men was examined in the present study. We found that the prevalence rates of HPV infection among Japanese men who attended an STD clinic were 18.8% and 22.1% in oral and urine samples, respectively. This is the first study to compare the HPV detection rate of the oral cavity and urine, and the HPV detection rate in the oral cavity was similar to that in urine among these subjects.

D'Souza *et al.* investigated the prevalence of oropharyngeal HPV infection using mouthwash among 332 control patients who attended an outpatient otolaryngology clinic and 210 college-age men in the USA [18]. HPV infection was detected in 4.8% of 332 control patients from the outpatient clinic and in 2.9% of 210 college-age men,

Table 4 Details of HPV types in cases in which HPV was detected from both oral and urine samples

	Oral cavity	Urine
Case 1	16	16, 52
Case 2	16	16, 18
Case 3	16, 33	11, 16, 33
Case 4	16, 33	33
Case 5	16, 33	16, 33
Case 6	18	18
Case 7	18	18
Case 8	6	18
Case 9	6, 16	6
Case 10	16	16, 53
Case 11	16	6, 16
Case 12	6	6
Case 13	16	16
Case 14	16	16
Case 15	16	16
Case 16	6, 11	11
Case 17	18	11
Case 18	18	18

HPV was detected in both oral and urine samples from 16 cases.
 HPV, human papillomavirus.

and the increased lifetime numbers of oral sex partners or open-mouth kissing partners were found to be risk factors for oral HPV infection. Kreimer *et al.* detected oral HPV infection in 4.0% (67 cases) of 1608 healthy men aged 18 – 78 from the USA, Mexico, and Brazil using the Roche linear array HPV genotyping assay [19]. In addition, a recent systematic review indicated that 1.3% of 3977 healthy subjects had oral HPV16, 3.5% of 4441 subjects had high-risk HPV, and 4.5% of 4070 subjects were positive for any HPV. Men and women had similar prevalence rates of any oral HPV (4.6% and 4.4%, respectively) [20]. These previous reports suggest that the oropharyngeal HPV prevalence rate among healthy subjects is approximately 3% – 4%, and that HPV is rarely detected in oral specimens compared with genital or urine samples from healthy individuals.

However, the prevalence in our subjects (18.8%) was much higher compared with those reported in previous studies, which was likely due to the difference in study populations. Our study was performed in male patients who attended an STD clinic, and therefore they represented a population that would have risk factors for sexually transmitted infection. Indeed, the prevalence of oral HPV infection in women was also reported to differ according to the study population, and its prevalence was higher (23.6%) in women who attended STD outpatient clinics [21] compared with healthy women [22,23].

In addition, a cohort study of 212 men aged 18 – 24 indicated that nearly 20% of sexually active male university students had evidence of oral HPV infection within 12 months [24]. Moreover, the HPV prevalence rate in oral samples among our subjects was approximately equivalent to that in urine samples, which is a common HPV detection site in sexual active men [11,25]. Oral HPV infection may also be a sexually transmitted infection similar to genital HPV infection. However, in the present study there was a lack of data regarding the ways and frequencies of sexual contact or number of sexual partners in our population. Further epidemiological studies including such sexual information and healthy controls are required to reach more definitive conclusions.

We found that type-specific HPV prevalence was similar in oral and urinary samples, and HPV16 was the most common type identified in the present study. In addition, the majority of men with HPV infection in both the oral cavity and urine specimens had concordant oral and urinary HPV infection, suggesting that oral HPV infection in men may also occur through oral and genital contact with women. Indeed, the present study demonstrated that the presence of urinary HPV infection is an independent risk factor for oral HPV infection, with an odds ratio of 3.39.

Moreover, single-type HPV infection was frequently identified in the oral cavity, and single HPV16 was the most common type. Many epidemiologic studies indicated that HPV16 is the most common HPV type detected from HPV-associated OSCC [17,18], which is consistent with our findings. Multiple-type HPV infection is commonly observed in the cervix of women, low-grade cervical intraepithelial neoplasia (CIN), and male external genitalia. On the other hand, single-type HPV infection is an indicator of high-grade CIN or cervical cancer [26]. Although this difference between oral and urinary HPV infection has not been clarified, the oral cavity in men may be easily infected by HPV16. Alternatively, HPV16 infection may be persistent in the oral cavity in men. However, further studies of the natural history of oral HPV infection in men are required to confirm this hypothesis.

We performed another additional study to investigate the possible associations between oral HPV infection and other organisms responsible for sexually transmitted infections (STIs). In a previous study, we investigated the prevalence rates of *Mycoplasma* spp. and *Ureaplasma* spp. using liquid-based cytology samples of urine [25]. *M. genitalium*, *M. hominis*, *Ureaplasma parvum*, and *Ureaplasma urealyticum* were detected in 14.5%, 10.9%, 6.5%, and 12.3% of men with urethritis, whereas these species were detected in 3.3%, 2.0%, 4.7%, and 2.7% of controls, respectively [25]. Takahashi *et al.* also reported prevalence rates of 1%, 4%, 12%, and 23% for *M. genitalium*, *M. hominis*, *U. parvum*, and *U. urealyticum*,

Table 5 Univariate and multivariate analyses of risk factors for detection of any HPV infection in oral samples

Variables	n	Oral HPV infection		Univariate analysis			Multivariate analysis		
		Positive	Negative	Odds ratio	95% CI	P	Odds ratio	95% CI	P
Age (yo)									
< 35	115	23	92	1.0 (referent)			1.0 (referent)		
≥ 35	98	17	81	0.65	0.12–1.70	0.647	0.71	0.32–1.58	0.402
Urine HPV infection									
negative	167	22	145	1.0 (referent)			1.0 (referent)		
positive	46	18	28	4.24	2.02–8.91	<0.001	3.39	1.49–7.71	0.004
Urethritis									
negative	122	28	94	1.0 (referent)			1.0 (referent)		
positive	91	12	79	0.51	0.24–1.07	0.0711	0.78	0.32–1.81	0.532
Oral samples									
<i>N. gonorrhoeae</i>: negative									
	177	38	139	1.0 (referent)			1.0 (referent)		
positive	36	2	34	0.22	0.05–0.94	0.016	0.096	0.01–0.77	0.027
<i>C. trachomatis</i>: negative									
	204	39	165	1.0 (referent)			1.0 (referent)		
positive	9	1	8	0.53	0.06–4.35	0.470	0.39	0.03–4.69	0.460
<i>M. genitalium</i>: negative									
	202	39	163	1.0 (referent)			1.0 (referent)		
positive	11	1	10	0.42	0.05–3.36	0.353	0.28	0.02–3.10	0.296
<i>M. hominis</i>: negative									
	191	35	156	1.0 (referent)			1.0 (referent)		
positive	22	5	17	1.31	0.45–3.79	0.398	0.68	0.10–4.50	0.692
<i>Ureaplasma</i>: negative									
	179	33	146	1.0 (referent)			1.0 (referent)		
positive	34	7	27	1.15	0.46–2.86	0.464	0.52	0.09–3.16	0.478
Any organisms: negative									
	126	26	100	1.0 (referent)			1.0 (referent)		
positive	87	14	73	0.74	0.36–1.51	0.405	3.84	0.59–27.92	0.184
Urine samples									
<i>N. gonorrhoeae</i>: negative									
	194	38	156	1.0 (referent)			1.0 (referent)		
positive	19	2	17	0.48	0.11–2.18	0.267	0.56	0.04–7.62	0.663
<i>C. trachomatis</i>: negative									
	180	38	142	1.0 (referent)			1.0 (referent)		
positive	33	2	31	0.24	0.06–1.05	0.051	0.21	0.02–2.10	0.186
<i>M. genitalium</i>: negative									
	197	39	158	1.0 (referent)			1.0 (referent)		
positive	16	1	15	0.27	0.04–2.11	0.158	0.64	0.05–8.77	0.737
<i>M. hominis</i>: negative									
	200	38	162	1.0 (referent)			1.0 (referent)		
positive	13	2	11	0.78	0.17–3.64	0.545	0.42	0.06–2.96	0.380
<i>Ureaplasma</i>: negative									
	173	31	142	1.0 (referent)			1.0 (referent)		
positive	40	9	31	1.33	0.58–3.07	0.320	1.29	0.12–10.60	0.814
Any organisms: negative									
	116	26	90	1.0 (referent)			1.0 (referent)		
positive	97	14	83	0.58	0.29–1.19	0.140	0.94	0.09–9.43	0.958

HPV, human papillomavirus.

respectively, in urine samples from 100 asymptomatic healthy Japanese men [27]. These findings are different from the present results. In particular, *M. genitalium* has been widely accepted as an agent of STIs, and the differences between these studies may have been due to differences in the sample size and characteristics of the study populations as well as the detection methods used. On the

other hand, little information is available regarding the prevalence rates of *Mycoplasma* spp. and *Ureaplasma* spp. in the male oral cavity. Sackel et al. reported that *M. hominis* and *Ureaplasma* spp. were recovered from pharyngeal samples obtained from 149 (14.3%) and 154 (14.8%), respectively, of 1044 men and women who attended clinics in Boston, USA, which were equivalent to the findings of

the present study [28]. There were no significant differences in the detection rates of *M. genitalium*, *M. hominis*, and *Ureaplasma* spp. in males between the oral cavity and urine samples, suggesting that genital *Mycoplasma* spp. and *Ureaplasma* spp. could frequently infect the male oral cavity.

It has been reported that the presence of infection in the urinary tract is an independent risk factor for HPV infection [15]. HPV generally infects the basal layer of the mucosa, and inflammation and microinjury of the urothelium caused by *N. gonorrhoeae*, *C. trachomatis*, and/or *M. genitalium* are likely to facilitate access of HPV to the basal cells of the urothelium in the urethra. However, multivariate analysis indicated that oral gonococcal infection was a negative factor for oral HPV infection in the present study. One possible reason for this observation is that there were no patients with pharyngitis-like symptoms. Most oropharyngeal gonococcal or chlamydial infections are asymptomatic without inflammation of the oropharynx [29], and it may not be possible to demonstrate that other isolated microorganisms, such as *N. gonorrhoeae*, *C. trachomatis*, and *M. genitalium*, were risk factors for the detection of oral HPV infection. Alternatively, the population size in the present study was small, and further large-scale studies will be required to reach more definitive conclusions.

In the present study, a liquid-based cytological procedure, which is commonly used in cervical cancer screening, was used for detection of HPV in oropharyngeal gargle and urine samples. Urine is generally considered unsuitable for the detection of HPV due to the poor β -globin detection rate (< 50%) [30]. However, our previous study indicated that the liquid-based cytological procedure is useful for HPV detection in urine samples from men, and we found that the detection rate of the β -globin gene was > 97% in urine from healthy men and male patients with urethritis [25]. We found an excellent detection rate (100%) of β -globin in oropharyngeal gargle samples using a liquid-based cytological procedure, suggesting that this method, which is recommended for testing oropharyngeal STIs, such as *N. gonorrhoeae*, *C. trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp., is also suitable for detection of HPV in oropharyngeal gargle samples.

Conclusion

In conclusion, oral HPV infection is common in sexually active men, and its prevalence rate was equivalent to that in urine samples. In addition, oral HPV infection was significantly correlated with urinary HPV infection.

Abbreviations

HPV: Human papillomavirus; OSCC: Oropharyngeal squamous cell carcinoma; STD: Sexually transmitted disease; PCR: Polymerase chain reaction; CIN: Cervical intraepithelial neoplasia; STI: Sexually transmitted infection.

Competing interests

The authors declare they have no conflicts of interest.

Authors' contributions

All authors made substantial contributions to conception and design, or acquisition of data. KN, KS, and SK were in charge of the analysis and interpretation of all data. KN drafted major portions of the initial manuscript, and KS, TS, and MN helped in writing the final manuscript. All authors have read and approved the final manuscript.

Author details

¹Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. ²Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan. ³Wakatsuki Clinic, Osaka City, Osaka, Japan. ⁴Department of Urology, Dokkyo Medical School, Koshigaya Hospital, Koshigaya, Saitama, Japan. ⁵Nakashima Clinic, Kanazawa, Ishikawa, Japan. ⁶Ishii Clinic, Saitama City, Saitama, Japan. ⁷Department of Obstetrics & Gynecology, Kanazawa Medical School, Kahoku-gun, Ishikawa, Japan.

Received: 12 August 2013 Accepted: 23 January 2014

Published: 27 January 2014

References

1. Zur HH: Papillomavirus infections: a major cause of human cancers. *Biochem Biophys Acta* 1996, **1288**:F55–78.
2. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S: Human papillomavirus prevalence and type distribution in penile carcinoma. *J Clin Pathol* 2009, **62**:870–878.
3. Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. *Int J Cancer* 2009, **124**:2375–2383.
4. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin Oncol* 2008, **26**:612–619.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011, **29**:4294–4301.
6. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med* 2010, **363**:24–35.
7. Tanaka S, Sobue T: Comparison of oral and pharyngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960–2000). *Jpn J Clin Oncol* 2005, **35**:488–491.
8. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000, **92**:709–720.
9. Smith JS, Melendy A, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review. *J Adolesc Health* 2008, **43**(Suppl):S5–25.
10. Yamada R, Sasagawa T, Kirumbi LW, Kingoro A, Karanja DK, Kiptoo M, Nakitare GW, Ichimura H, Inoue M: Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. *J Med Virol* 2008, **80**:847–855.
11. Shigehara K, Sasagawa T, Kawaguchi S, Kobori Y, Nakashima T, Shimamura M, Taya T, Furubayashi K, Namiki M: Prevalence of human papillomavirus infection in the urinary tract of men with urethritis. *Int J Urol* 2010, **17**:563–568.
12. Grisaru D, Avidor B, Niv J, Marmor S, Almog B, Leibowitz C, Graidy M, Giladi M: Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. *J Clin Microbiol* 2008, **46**:1602–1605.
13. Chaudhry U, Saluja D: Detection of *Neisseria gonorrhoeae* by PCR using *orf1* gene as target. *Sex Transm Infect* 2002, **78**:72–78.
14. Mahony JB, Song X, Chong S, Faught M, Salonga T, Kapala J: Evaluation of the NucliSens Basic Kit for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in genital tract specimens using nucleic acid sequence-based amplification of 16S rRNA. *J Clin Microbiol* 2001, **39**:1429–1435.

15. Shigehara K, Kawaguchi S, Sasagawa T, Furubayashi K, Shimamura M, Maeda Y, Konaka H, Mizokami A, Koh E, Namiki M: **Prevalence of genital Mycoplasma, Ureaplasma, Gardnerella, and human papillomavirus in Japanese men with urethritis, and risk factors for detection of urethral human papillomavirus infection.** *J Infect Chemother* 2011, **17**:487–492.
16. Stellrecht KA, Woron AM, Mishrik NG, Venezia RA: **Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas.** *J Clin Microbiol* 2004, **42**:1528–1533.
17. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: **Case-control study of human papillomavirus and oropharyngeal cancer.** *N Engl J Med* 2007, **356**:1944–1956.
18. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML: **Oral sexual behaviors associated with prevalent oral human papillomavirus infection.** *J Infect Dis* 2009, **199**:1263–1269.
19. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, Hildesheim A, Villa LL, Lazcano-Ponce E, Giuliano AR: **The epidemiology of oral HPV infection among a multinational sample of healthy men.** *Cancer Epidemiol Biomarkers Prev* 2011, **20**:172–182.
20. Kreimer AR, Bhatia RK, Messegue AL, González P, Herrero R, Giuliano AR: **Oral human papillomavirus in healthy individuals: a systematic review of the literature.** *Sex Transm Dis* 2010, **37**:386–391.
21. Marais DJ, Passmore JA, Denny L, Sampson C, Allan BR, Williamson AL: **Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa.** *J Med Virol* 2008, **80**:953–959.
22. Smith EM, Ritchie JM, Yankowitz J, Wang D, Turek LP, Haugen TH: **HPV prevalence and concordance in the cervix and oral cavity of pregnant women.** *Infect Dis Obstet Gynecol* 2004, **12**:45–56.
23. Fakhry C, D'Souza G, Sugar E, Weber K, Goshu E, Minkoff H, Wright R, Seaberg E, Gillison M: **Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women.** *J Clin Microbiol* 2006, **44**:4479–4485.
24. Edelstein ZR, Schwartz SM, Hawes S, Hughes JP, Feng Q, Stern ME, O'Reilly S, Lee SK, Fu Xi L, Koutsky LA: **Rates and determinants of oral human papillomavirus infection in young men.** *Sex Transm Dis* 2012, **39**:860–867.
25. Kawaguchi S, Shigehara K, Sasagawa T, Shimamura M, Nakashima T, Sugimoto K, Nakashima K, Furubayashi K, Namiki M: **Liquid-based urine cytology as a tool for detection of human papillomavirus, Mycoplasma spp., and Ureaplasma spp. in men.** *J Clin Microbiol* 2012, **50**:401–406.
26. Sasagawa T, Basha W, Yamazaki H, Inoue M: **High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women.** *Cancer Epidemiol Biomarkers Prev* 2001, **10**:45–52.
27. Takahashi S, Takeyama K, Miyamoto S, Ichihara K, Maeda T, Kunishima Y, Matsukawa M, Tsukamoto T: **Detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum DNAs in urine from asymptomatic healthy young Japanese men.** *J Infect Chemother* 2006, **12**:269–271.
28. Sackel SG, Alpert S, Fiumara NJ, Donner A, Laughlin CA, McCormack WM: **Orogenital contact and the isolation of Neisseria gonorrhoeae, Mycoplasma hominis, and Ureaplasma urealyticum from the pharynx.** *Sex Transm Dis* 1979, **6**:64–68.
29. Peters RP, Nijsten N, Mutsaers J, Jansen CL, Morré SA, van Leeuwen AP: **Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors.** *Sex Transm Dis* 2011, **38**:783–787.
30. Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB: **The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study.** *J Infect Dis* 2007, **196**:1146–1152.

doi:10.1186/1471-2334-14-43

Cite this article as: Nakashima et al.: Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Mycoplasma* spp., and *Ureaplasma* spp. *BMC Infectious Diseases* 2014 **14**:43.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

